SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02419287
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
The purpose of this study is to determine the response and the duration of it in patients
affected by ALK+ lymphoma that are resistant or refractory to standard cytotoxic treatment
that will be treated with crizotinib.
Name: crizotinib
Type: Drug
Group Labels: 1 crizotinib
Primary Outcomes
Measure: objective response rates (ORR) in subjects with ALK+ lymphomas resistant or refractory to standard cytotoxic treatment, according to RECIST 1.1 criteria. Time: the entire duration of the study (5 years)
Measure: Duration ORR Time: the entire duration of the study (5 years)
Secondary Outcomes
Measure: Progression free survival (PFS) in ALK+ lymphoma patients treated with crizotinib, that are resistant or refractory to standard cytotoxic treatment. Time: the entire duration of the study (5 years)
Measure: Number of patients with adverse events after crizotinib treatment Time: the entire duration of the study (5 years)
Measure: Quality of Life (QoL) in this population of patients using the the EORTC - C30 Quality of Life questionnaire Time: the entire duration of the study (5 years)
Measure: Overall survival (OS) in ALK+ lymphoma patients treated with crizotinib Time: the entire duration of the study (5 years)
Purpose: Treatment
Allocation: N/A
Single Group Assignment
There is one SNP
SNPs
1 I1171N
Although crizotinib shows activity, relapses occur typically within 5 months after starting
treatment and were supported by mutations like I1171N. --- I1171N ---